Reference desk / Entry
Semaglutide
Also listed as: Wegovy
Read the scope first. Then use the note and questions to examine what the evidence can answer.
- Scoped product status
- Approved product
- Evidence label
- Randomized evidence
- Status as of
Reference fields
References for these fields are listed together in Sources.
- Product and use scope
- Wegovy injection: weight management in eligible adults.
- Route context
- This entry covers subcutaneous Wegovy injection.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- Severe or persistent gastrointestinal symptoms: contact a clinician.
A question worth making clear
Give a discussion a common starting point by writing the comparison as a complete question. Name what is being considered, the alternative it is being compared with, and the result that would distinguish them. Invite another reader to describe that same question in their own words. If the descriptions differ, settle the difference before debating a result. A report might answer one comparison accurately while leaving a nearby comparison open. Making the alternatives explicit helps everyone see which answer is needed and whether the cited evidence supplies it.
- What are the two alternatives in the question we want this report to answer?
- Would another reader describe the same comparison from the wording we have chosen?
- Which part of our comparison is addressed directly, and which part remains open?
Sources
Each date below belongs to the supplied source record. The references support the entry as a group.
- WEGOVY
NLM · Checked
- Wegovy approval
FDA · Checked